Atlas One · Host Biology · Scale 03 — Molecular

DLL3

DLL3 (Delta-like ligand 3) is an inhibitory Notch ligand overexpressed in >80% of SCLC and neuroendocrine carcinomas; DLL3 cis-inhibits Notch1/2 on tumor cells; tarlatamab (DLL3×CD3 bispecific antibody, FDA 2024) is approved for relapsed/refractory SCLC.

Also known as: DLL3, Delta-like ligand 3, DLL3 SCLC, tarlatamab target, DLL3 bispecific, neuroendocrine DLL3, DLL3 ADC, rovalpituzumab target

Scale 03 — MolecularScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
dll3

DLL3

DLL3 (Delta-like ligand 3) is an inhibitory Notch ligand overexpressed in >80% of SCLC and neuroendocrine carcinomas; DLL3 cis-inhibits Notch1/2 on tumor cells; tarlatamab (DLL3×CD3 bispecific antibody, FDA 2024) is approved for relapsed/refractory SCLC.

Entry Metadata

FieldValue
IDdll3
NameDLL3
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale03-molecular

Cross-Atlas Connections

connects-toNotch connects-toRb1 connects-toP53 connects-toSstr2 connects-toSclc connects-toT Cytotoxic Cell connects-toLung

Sources